These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 8405374)

  • 1. Evidence for three binding sites for C3 (hemolytically inactive), C3b and C3d on a CR2-positive Burkitt lymphoma-derived cell line (Raji).
    Barile G; Di Renzo L; Lipari M; Frati L; Faggioni A
    FEBS Lett; 1993 Jun; 324(3):319-24. PubMed ID: 8405374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.
    Molina H; Kinoshita T; Webster CB; Holers VM
    J Immunol; 1994 Jul; 153(2):789-95. PubMed ID: 8021513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histochemical contributions to the binding mechanism of complement (CR1, CR2) receptors.
    Baranyay F
    Pathol Oncol Res; 2009 Dec; 15(4):639-44. PubMed ID: 19353305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
    Vik DP; Fearon DT
    J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified from spleen cells.
    Pramoonjago P; Takeda J; Kim YU; Inoue K; Kinoshita T
    Int Immunol; 1993 Apr; 5(4):337-43. PubMed ID: 7684250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative evaluation of receptor reactivities for C3b, iC3b, and C3d on Raji lymphoblastoid cells.
    Scheiner O; Hammann KP; Schmid HU; Schulz T; Alsenz J; Dierich MP
    Int Arch Allergy Appl Immunol; 1982; 69(3):231-7. PubMed ID: 6215359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
    Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
    J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.
    Weis JJ; Tedder TF; Fearon DT
    Proc Natl Acad Sci U S A; 1984 Feb; 81(3):881-5. PubMed ID: 6230668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
    J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
    Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
    Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-linking of at least three binding sites mediates signal transduction in a CR2-positive Burkitt lymphoma derived cell line (Raji).
    Barile G; Pernozzoli B; Tiracchia V; Ioppolo S; De Cristofaro M; Mattei E; Faggioni A
    FEBS Lett; 1995 Sep; 372(2-3):291-6. PubMed ID: 7556687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of C3-binding proteins on mouse neutrophils and platelets.
    Quigg RJ; Alexander JJ; Lo CF; Lim A; He C; Holers VM
    J Immunol; 1997 Sep; 159(5):2438-44. PubMed ID: 9278336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
    Carel JC; Myones BL; Frazier B; Holers VM
    J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
    J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres.
    Lambris JD; Ross GD
    J Immunol; 1982 Jan; 128(1):186-9. PubMed ID: 7033372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.